cellular assay development for the endothelial differentiation gene (EdG) family of G-protein-coupled receptors (GpcRs) and related lysophospholipid (lp) receptors is complicated by endogenous receptor expression and divergent receptor signaling. Endogenously expressed lp receptors exist in most tissue culture cell lines. these lp receptors, along with other endogenously expressed GpcRs, contribute to off-target signaling that can complicate interpretation of second-messenger-based cellular assay results. these receptors also activate a diverse and divergent set of cellular signaling pathways, necessitating the use of a variety of assay formats with mismatched procedures and functional readouts. this complicates examination and comparison of these receptors across the entire family. the tango technology uses the conserved β-arrestin-dependent receptor deactivation process to allow interrogation of the EdG and related receptors with a single functional assay. this method also isolates the target receptor signal, allowing the use of tissue culture cell lines regardless of their endogenous receptor expression. the authors describe the use of this technique to build cell-based receptor-specific assays for all 8 members of the EdG receptor family as well as the related lpa receptors GpR23, GpR92, and GpR87. in addition, they demonstrate the value of this technology for identification and investigation of functionally selective receptor compounds as demonstrated by the immunosuppressive compound Fty720-p and its action at
INTRODUCTION
L ysophospholipids (LPS), lysophosphatidic acid (LPA), and sphingosine-1-phosphate (s1p) regulate varied biological processes through their activity at G-protein-coupled receptors (GpcRs), including the 8 members of the endothelial differentiation gene (EdG) family. the EdG receptor family comprises 3 lpa responsive receptors-EdG 2 (lpa 1 ), EdG 4 (lpa 2 ), and EdG 7 (lpa 3 )-and 5 s1p responsive receptors: EdG 1 (s1p 1 ), EdG 3 (s1p 3 ), EdG 5 (s1p 2 ), EdG 6 (s1p 4 ), and EdG 8 (s1p 5 ). 1 Beyond the EdG receptor family, there are 4 additional distantly related lpa receptors: GpR23 (lpa 4 ), GpR92 (lpa 5 ), GpR87, and the only proposed dual s1p/lpa receptor, p2y 10 . [2] [3] [4] [5] collectively, these lps receptors are involved in numerous biologically important processes and have implicated involvement in several disease disorders (for a review, see Gardell et al. 6 ). cellular assay development for this group of receptors is complicated by their semi-ubiquitous family expression profile and their diverse and divergent signaling pathway activation. Endogenously expressed lpa and s1p receptors are present in many commonly used tissue culture cell lines, leaving the cell lines with some level of endogenous second-messenger activity to these compounds, which results in signaling that is not modulated through the target receptor. 7, 8 the receptors differentially signal through G q/11 , G s , G i , and G 12/13 G-proteins to activate varied cellular signaling cascades. there is no single G-proteindependent cellular signaling pathway that is activated by all EdG receptor family members that can be exploited for uniform cellular assay development. the ability to isolate target receptor signaling regardless of the endogenous receptor background and unite all receptors into a single assay format is key to the successful development of functional cellular assays for this receptor group.
agonist-induced receptor activation stimulates β-arrestindependent receptor internalization, regardless of a receptor's second-messenger pathway signaling preference. this recruitment of β-arrestin can be monitored by the use of several technologies that use a combination of a chimeric β-arrestin paired with a chimeric GpcR to drive reporter gene readouts through either enzyme complementation or transcriptional activation (for a review of technologies available for GpcR assay development, see hanson and hanson 9 ).
the tango assay technology employs the highly conserved GpcR β-arrestin recruitment and deactivation process to measure receptor activation in a live-cell assay format. to accomplish this, the technology uses a protease-linked β-arrestin fusion protein paired with a target GpcR that is c-terminally tagged with a transcription factor via a β-arrestin/proteasespecific cleavage site. Both the β-arrestin and GpcR fusion proteins are then expressed in a cell line containing a transcription factor-selective response element-driven β-lactamase reporter construct. target GpcR activation leads to arrestinprotease recruitment and proteolitic release of the transcription factor, allowing activation of reporter gene expression, which can be used to quantify target receptor activity. [10] [11] [12] the use of this conserved receptor action for development of high-throughput GpcR cellular assays not only allows for the interrogation of a majority of GpcRs using a single unified cellular assay format but can also be used in conjunction with other assay formats to gain a deeper understanding of a compound's functional properties. in the case of the s1p receptors, the assay format measures the clinically relevant functional response of the only known EdG receptor-targeting therapeutic compound, Fingolimod (Fty720). Fty720 is a novel immunosuppressant that is currently in phase iii clinical trials for relapsing multiple sclerosis and has completed phase iii clinical trials for prevention of renal transplant rejection. in vivo, phosphorylated Fty720 (Fty720-p) sequesters t cells in the secondary lymphoid tissue by reducing EdG 1 cell surface levels through agonist-induced receptor internalization and degradation. 13 these EdG 1 receptor-depleted activated t cells are then unable to follow a natural concentration gradient of s1p from the lymphoid tissue into the circulatory system. 13 Fty720-p has also been established to be a high-affinity agonist at 3 of the other 4 s1p-responsive EdG receptors, raising the compound's potential for off-target side effects. 13 in fact, Fty720-p activity at the EdG 3 receptor has been demonstrated to induce transient bradycardia in clinical trials, and some research suggests Fty720-p has the potential to cause adverse cardiofibrotic effects through activation of myofibroblast differentiation. 14, 15 additional studies have reported that Fty720-p has functionally selective activity at the EdG 3 receptor, selectively activating G i -coupled G-protein signaling but not activating G q -coupled signaling or the stimulation of β-arrestin recruitment and receptor internalization. 16 this is in contrast to s1p, which activates all 3 actions through the EdG 3 receptor. these findings implicate that the G i -protein-associated activity of Fty720-p at EdG 3 is responsible for the compound's side affects. the findings are also suggestive that identification of compounds with functionally selective activities at related EdG receptors is critical for the development of therapeutics that target this receptor family.
We describe here the use of the tango technology platform to construct cellular assays for all 8 members of the EdG receptor family and the distantly related lpa receptors GpR23, GpR92, and GpR87. We demonstrate here how this technology can be used to unite receptors with varied G-protein-dependent second-messenger signaling under a single universal assay formant that isolates target receptor activity from endogenously expressed receptors. in addition, we demonstrate the ability of the technology to identify receptor-selective compound activity that could be useful in guiding the development of therapeutic compounds with less potential for adverse side effects.
MATERIALS AND METHODS

Materials
the tango GpcR U2os cell line, GeneBlazer  EdG 3 Gα15 NFat-bla hEK, and tango GpcR expression vector plasmids were obtained from invitrogen discovery assays and services (Madison, Wi). lpa (1-oleoyl-2-hydroxy-sn-Glycero-3-phosphate), s1p, Vpc32183, and Vpc23019 were purchased from avanti polar lipids (alabaster, al). Fty720 was purchased from EMd (Gibbstown, NJ), and Fty720-p was purchased from toronto Research chemicals (North york, ontario). JtE-013 and cay-10444 were purchased from cayman chemical (ann arbor, Mi). all cell culture components, transfection reagents, phosphate-buffered saline (pBs), and bovine serum albumin (Bsa) were obtained from invitrogen (carlsbad, ca). six-well tissue culture plates and black 384-well assay plates with clear bottom with or without cellBiNd  coating were from costar (cambridge, Ma).
Cell line construction
the tango EdG 1-8 , GpR23, GpR92, and GpR87 cell lines were constructed by stable transfection of expression plasmids encoding modified receptor fusion proteins into the tango GpcR U2os cell line. then, 1 × 10 6 cells were plated in Mccoy's 5a medium supplemented with 10% dialyzed fetal bovine serum (FBs), 25 mM hEpEs buffer (ph 7.3), 0.1 mM nonessential amino acids, and 1 mM sodium pyruvate into a 6-well tissue culture plate and placed at 37 °c 5% co 2 for 16 h. the cells were then transfected with receptor expression plasmids using lipofectamine ltX and plus reagent as directed by the manufacture protocol. stable transfected cell pools were then created by selection with 200 µg/ml Geneticin  for 2 to 4 weeks. the stable cell pools were then tested for a response to the reported receptor ligand (lpa or s1p). if the response in the antibiotic selected pool was not sufficiently robust, then ligandresponsive enriched pooled populations and clones were collected using fluorescence-activated cell sorting (Facs).
Cell culture
the tango cell lines were maintained in Mccoy's 5a medium supplemented with 10% dialyzed FBs (dFBs), 25 mM hEpEs buffer (ph 7.3), 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, penicillin/streptomycin, 200 µg/ ml Zeocin, 100 µg/ml geneticin, and 50 µg/ml hygromycin in a humidified incubator at 37 °c with 5% co 2 . the EdG 3 Gα15 NFat-bla hEK and Gα15 NFat-bla hEK cell line were maintained in dulbecco's modified Eagle's medium (dMEM) supplemented with 10% charcoal-stripped FBs, 25 mM hEpEs buffer (ph 7.3), 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, and penicillin/streptomycin in a humidified incubator at 37 °c with 5% co 2 .
Beta-lactamase reporter assay
the tango receptor cell lines were plated at 10,000 cells/ well in Freestyle Expression Medium into 384-well assay plates. the cells were then incubated at 37 °c with 5% co 2 for 16 to 48 h depending on the receptor expressed. For agonist assays, the cell lines were then exposed to lpa, s1p, or another agonist compound in Freestyle Expression Medium for 5 h at 37 °c with 5% co 2 . For antagonist assays, the cell lines were exposed to antagonist compound for 30 to 60 min prior to treatment with an Ec80 concentration of s1p or lpa for 5 h at 37 °c with 5% co 2 . after agonist exposure, the cells were loaded with liveBlazer FREt B/G substrate (invitrogen) for 2 h at room temperature. then using 409 nm excitation, the fluorescence emission values at 460 nm and 530 nm were obtained using a tecan infinite  fluorescence plate reader.
the tango GpR23, GpR92, and GpR87 receptor cell lines were plated at 10,000 cells/well in Freestyle Expression Medium into 384-well assay plates. the cells were then serum starved at 37 °c with 5% co 2 for 24 h and then exposed to lpa or dFBs in Freestyle Expression Medium for 48 h at 37 °c with 5% co 2 and loaded with liveBlazer FREt B/G substrate and analyzed as described above.
the GeneBlazer EdG3 Gα15 NFat-bla hEK and Gene-Blazer Gα15 NFat-bla hEK cell lines were plated at 10,000 cells/well in optiMEM medium supplemented with 2% charcoal-stripped FBs and incubated at 37 °c with 5% co 2 for 16 h. the medium was then replaced with dMEM containing 0.1% Bsa, and the cells were exposed to s1p or other agonists for 5 h at 37 °c with 5% co 2 and then loaded with liveBlazer FREt B/G substrate and analyzed as described above.
Data analysis
Background fluorescence values for each emission wavelength were obtained from cell-free wells containing assay Medium and liveBlazer FREt B/G substrate and subtracted from the fluorescent values of the test wells. the backgroundcorrected fluorescence emission values at 460 nm were divided by the 530-nm value to obtain a 460-nm/530-nm ratio. the total response (response ratio) of the sample was then calculated by dividing the 460-nm/530-nm ratio of the agonist-treated sample by the 460-nm/530-nm ratio of an agonist-untreated control sample. all data were graphed in % activation, with 100% activation being set to the maximum stimulation observed at full primary agonist (lpa or s1p) concentration.
RESULTS AND DISCUSSION
to construct cell-based assays for the EdG family of receptors and the related lpa receptors (GpR23, GpR87, and GpR92), we had to overcome 2 obstacles that are associated with traditional second-messenger assays that detect calcium flux, caMp modulation, or cellular pathway activation via reporter genes. First, we needed to isolate the target receptor signal from any endogenous GpcR signals that could produce a false off-target positive result. all mammalian tissue culture cells express a varied collection of GpcRs, and most of these cell lines have some lpa or s1p receptor expression. the second obstacle for the construction of cellular assays for the EdG and related receptors is the lack of a single unifying G-protein-dependent assay platform that can identify activity of all members of the family. this necessitates the use of multiple assay platforms with varied reagent and equipment requirements for EdG receptor family interrogation. to circumvent the complexities of development using multiple analysis platforms and to mitigate the effects of endogenous GpcRs, we employed the tango assay technology to construct cellular assays for the EdG family of receptors.
Parental cell line evaluation
the parental tango GpcR U2os cell line was examined to confirm that it would not demonstrate a β-lactamase reporter response in the absence of an expressed modified receptor. this cell line expresses a tobacco etch virus (tEV) protease/β-arrestin fusion protein and contains a Uas-bla reporter construct. the cell line can be used for the construction of GpcR-specific assays by stable expression of a tango-modified receptor. Modified receptors are fusion proteins that have a Gal4-Vp16 transcription factor attached at the cytoplasmic c-terminus of the receptor linked by a tEV N1a protease-specific cleavage site. Upon activation, the protease/β-arrestin2 is recruited to the receptor, where it is able to release the transcription factor that translocates to the nucleus and activates the expression of β-lactamase. β-lactamase expression is then measured using the liveBlazer FREt B/G substrate.
the parental cell line was assayed along with the positive control EdG 1 and EdG 2 receptor-expressing cell lines by exposing them to titrations of either lpa or s1p and assessing β-lactamase expression. the EdG 1 and EdG 2 receptorexpressing cell lines exhibit a dose-dependent β-lactamase reporter response to s1p and lpa, respectively. the parental cell line showed no s1p-or lpa-specific reporter gene activation (Fig. 1A) .
The Tango TM EDG receptor cellular assays demonstrate agonist specificity
once constructed, the EdG receptor cell lines were tested to confirm that the receptors demonstrated a correct agonistinduced β-lactamase reporter response to and specificity for their reported ligand (lpa or s1p).
the EdG 2 , EdG 4 , and EdG 7 receptor cell lines responded to lpa with Ec 50 values of 84 nM, 87 nM, and 1.9 µM, respectively ( Fig. 1B) . these results are consistent with published Ec 50 value ranges obtained using binding assays and calcium mobilization assays from 1 to 100 nM for EdG 2 , 1 to 50 nM for EdG 4 , and 250 to 1000 nM for EdG 7 . 17,18 the lpa receptor assay results were also in agreement with published data indicating EdG 7 to be a lower affinity lpa receptor than EdG 2 or EdG 4 . 17,18 the EdG 2 , EdG 4 , and EdG 7 cell lines were unresponsive to s1p (Fig. 1C) .
the EdG 1 , EdG 3 , EdG 5 , EdG 6 , and EdG 8 receptor cell lines responded to s1p with Ec 50 values of 8.6 nM, 12.7 nM, 13.4 nM, 26 nM, and 17 nM, respectively (Fig. 1C) , while showing no agonist-induced response to lpa (Fig. 1B) . these low nM Ec 50 values closely resemble published values for the receptors (2.7 nM, EdG 1 ; 5 nM, EdG 3 ; 7.1 nM, EdG 5 ; 46 nM, EdG 6 ; and 5.4 nM, EdG 8 ). [19] [20] [21] The Tango TM EDG receptor cellular assays show antagonist activity to confirm that the tango EdG receptor cell lines would show accurate antagonist compound activity, we tested them for the ability of reported receptor antagonists to inhibit an agonist-induced β-lactamase reporter response.
the response of the EdG 2 receptor cell line to lpa was partially inhibited by the compound Vpc32183. the ic 50 of Vpc32183 at EdG 2 was 283 nM, with 10 µM Vpc32183 inhibiting 65% of the cell line's response to lpa; 10 µM Vpc32183 fully inhibited the β-lactamase reporter response of the EdG 7 receptor cell line to lpa with an ic 50 value of 640 nM ( Fig. 2A) . published ic 50 values for Vpc32183 in Gtp[γ 35 s] binding assays were 604 nM for EdG 2 and 940 nM for EdG 7 . 22 the EdG 1 receptor cell line response to s1p was fully inhibited by the antagonist compound Vpc23019 with an ic 50 of 9.1 nM. the EdG 3 receptor cell line response to s1p was inhibited to 78% of the receptor response by 100 µM of the antagonist compound cay-10444 with an ic 50 of 4.6 µM. the EdG 5 and EdG6 cell lines both showed inhibition of s1p activation by JtE-013 with partial inhibition by the compound at the EdG 5 receptor and full inhibition at the EdG 6 receptor. the ic 50 values were 1.5 µM for EdG 5 and 4.5 µM for EdG 6 (Fig. 2B) . Tango TM GPR23, GPR92, and GPR87 respond to LPA to confirm that the recently deorphanized lpa receptors GpR23 (lpa 4 ), GpR92 (lpa 5 ), and GpR87 are responsive to lpa, we constructed tango cellular assays for each of the receptors and tested them for a response to lpa.
the GpR23, GpR92, and GpR87 cell lines were responsive to lpa at concentrations >10 µM (Fig. 3A) . during development of these cell lines, it was observed that the GpR23, GpR92, and GpR87 cell lines showed a β-lactamase reporter response to the dFBs in the culture medium that made serum starvation of the cell lines prior to assay necessary. a similar serum response had been observed with the other EdG receptor cell lines and is likely attributable to the presence of serum-born lps. to confirm that this activation was GpR23, GpR92, or GpR87 receptor specific, we serum starved the cell lines and then tested them along with the parental control cell line for a reporter response to increasing concentrations of dFBs and compared that response to 100 µM lpa. the GpR23, GpR92, and GpR87 cell lines responded to dFBs in a dose-dependent manner (Fig. 3B) , whereas the parental U2os cell line demonstrated no response to any concentration of dFBs or to 100 µM lpa (data not shown). the activation of GpR23, GpR92, and GpR87 receptors in response to 100 µM lpa was 50.6%, 52.6%, and 24.2%, respectively, as compared to the activation of the cell lines by 20% dFBs (which was set as 100% activation; Fig. 3B) .
Receptor expression in the GpR23, GpR92, and GpR87 cell lines was confirmed using a Vp16-specific antibody for FIG. 3. the GpR23, GpR92, and GpR87 receptors are responsive to high concentrations of lysophosphatidic acid (lpa) and serum.
(A) GpR23 (■), GpR92 (▲), and GpR87 (Δ) were assayed for a response to lpa. (B) the GpR23, GpR92, and GpR87 cell lines were assayed for a response to increasing concentrations of dFBs and 100 µM lpa. receptor detection and analyzed by using flow cytometry (data not shown). these data suggest that although all 3 receptors are responsive to lpa at µM concentrations, there may be other serum-born compounds that activate the GpR23, GpR92, and GpR87 receptors. alternatively, the response of these receptors to serum-born lpa may be potentiated by other serum components.
The S1P-selective EDG receptor cell lines respond to FTY720-P the immunomodulating compound Fty720 is phosphorylated in vivo to its medically active form Fty720-p, which functions through its activity on the EdG 1 receptor. Fty720-p has also been demonstrated to interact with and activate the other s1p-responsive EdG receptors to varying degrees. in addition, it has been reported that Fty720-p has functionally selective activity at the EdG3 receptor that leads to G-protein activation but does not signal for β-arrestin recruitment or receptor internalization. 16 consequently, Fty720-p would not be expected to exhibit any tango β-arrestin-based activity on the EdG3 receptor cell line. to further validate the functional efficacy of the tango EdG receptor cell lines, we evaluated the ability of Fty720 and Fty720-p to activate the s1p-responsive assays.
the tango EdG 1 receptor cell line demonstrated an Fty720-p-induced β-lactamase response that was equal in magnitude to that of s1p, whereas Fty720 was partially active, exhibiting a response equal to 40% of the EdG 1 receptor activation of 10 µM s1p (Fig. 4A) . Fty720-p demonstrates a 10-fold higher potency at the EdG 1 receptor than s1p and over a 100-fold greater potency than Fty720 at EdG 1 with Ec 50 values of 1 nM, 10.4 nM, and 171 nM, respectively (Fig. 4A) . Fty720 and Fty720-p also demonstrated agonist activities on the EdG 6 and EdG 8 receptors (Fig. 4B, Table 1 ). the EdG 1 , EdG 6 a, and EdG 8 receptor assays demonstrated the anticipated response and rank order potency to Fty720-p, with Ec 50 values closely matching published values. 23 Fty720-p partially activated the EdG 5 receptor in the tango assay format with the maximum response being equal to 60% of the receptor activation by 10 µM s1p (Fig. 4B) . Fty720-p has an Ec 50 value of 320 nM for the EdG 5 receptor in the tango assay format. Fty720 had no activity at the EdG 5 receptor (data not shown). Fty720-p has been previously demonstrated to have partial agonist activity (~35% receptor activation) with an Ec 50 value of >10,000 nM at the EdG 5 receptor, as determined by use of a Gtp[γ 35 s] binding assay. 23, 24 these data suggest that Fty720-p activates EdG 5 β-arrestin recruitment with a greater potency than its ability to activate G-proteins and that Fty720-p is a partial/low-affinity agonist at the EdG 5 receptor.
previous research has established that Fty720-p selectively activates only G i G-protein-mediated receptor signaling through the EdG 3 receptor without initiating β-arrestin recruitment and receptor internalization. 16 s1p, on the other hand, activates both G i and G q signaling and initiates receptor internalization. 16 in agreement with those findings, we observed that Fty720p does not activate the β-arrestin-dependent tango EdG 3 β-lactamase reporter response, whereas s1p does (Fig. 4C) . to confirm that Fty720-p is a functional agonist of the EdG 3 receptor, we tested the compound on the G i /G q pathway-based EdG 3 -Gα15-NFat-bla hEK cellular assay. the EdG 3 -Gα15 NFat-bla hEK cells were responsive to Fty720-p to the same degree and potency as they were to s1p, with Ec 50 values of 48 nM and 51 nM, respectively, whereas the parental Gα15-NFat bla hEK cell line gave no endogenous receptor response to either s1p or Fty720-p in the β-lactamase assay (Fig. 4C) .
our results confirm that Fty720-p demonstrates functionally selective activity on the EdG 3 receptor for G-protein activation without signaling for receptor internalization. Given that Fty720-p activity at EdG 3 is associated with induction of a transient bradycardia in clinical trials, the ability of the tango technology to identify related compounds that induce EdG 3 receptor internalization over G-protein activation could lead to drugs with beneficial immunosuppressant activity without offtarget cardiac effects.
CONCLUSIONS
the tango β-arrestin recruitment-based cellular assay platform provides a functional and unified high-throughput screening compatible format for the construction and evaluation of GpcR activity. this technology was used successfully to construct cellular assays for all 8 members of the EdG receptor family and the lpa receptors GpR23, GpR92, and GpR87. these assays were able to confirm the previously reported activity of agonist and antagonist compounds with excellent correlation to published results. the tango assay format also demonstrated the ability to isolate the target receptor-specific activity away from any endogenous receptor activation. in addition, the tango format has the potential to be used in the identification and examination of compounds with functionally selective receptor activities, increasing the precision of these compounds for their intended target activity.
